Inizio Taps Ryan Quigley as CEO

Inizio, a commercialization partner for health and life sciences companies, has appointed Ryan Quigley as Chief Executive Officer. Quigley succeeds Paul Taaffe, who will continue to work with Quigley to support the transition until the end of the year.

Quigley has served as Inizio’s Chief Operating Officer since 2021, driving the company’s commercial strategy, innovation agenda, and investment roadmap, as well as playing a role in developing Inizio into a leading commercialization partner to health and life sciences companies globally.

Liam FitzGerald, Chairman of the Board, said, “Ryan has an exceptional track record as a leader who combines strategic vision with deep operational expertise. He embodies the values of Inizio and has the energy, ambition and client focus to lead the business into its next chapter of growth and success.”

Prior to being appointed to his current role, Quigley’s 25-year career spanned some of the world’s largest healthcare and pharmaceutical companies. Most notably, he held senior leadership roles at Abbott and AbbVie, where he was responsible for launching blockbuster brands across major markets.

“This is an exciting time to lead Inizio as we continue to grow and help biopharma clients with integrated solutions to bring highly complex new drugs to market,” said Quigley. “Together, we will continue to unlock new opportunities, reimagine how healthcare engages with patients, professionals and society, and build on the momentum we have achieved over the last few years.”